Johan Vansteenkiste

927 total citations
29 papers, 714 citations indexed

About

Johan Vansteenkiste is a scholar working on Hematology, Biochemistry and Genetics. According to data from OpenAlex, Johan Vansteenkiste has authored 29 papers receiving a total of 714 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 16 papers in Biochemistry and 6 papers in Genetics. Recurrent topics in Johan Vansteenkiste's work include Erythropoietin and Anemia Treatment (27 papers), Iron Metabolism and Disorders (17 papers) and Blood transfusion and management (16 papers). Johan Vansteenkiste is often cited by papers focused on Erythropoietin and Anemia Treatment (27 papers), Iron Metabolism and Disorders (17 papers) and Blood transfusion and management (16 papers). Johan Vansteenkiste collaborates with scholars based in Belgium, United States and Austria. Johan Vansteenkiste's co-authors include John A. Glaspy, Heinz Ludwig, Jeffrey Crawford, David H. Henry, Dianne Tomita, Rafael G. Amado, Sudhakar Rao, Peter Bowers, Kenneth R. Bridges and Jesse A. Berlin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Johan Vansteenkiste

29 papers receiving 688 citations

Peers

Countries citing papers authored by Johan Vansteenkiste

Since Specialization

Citations

This map shows the geographic impact of Johan Vansteenkiste's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan Vansteenkiste with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan Vansteenkiste more than expected).

Fields of papers citing papers by Johan Vansteenkiste

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johan Vansteenkiste. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan Vansteenkiste. The network helps show where Johan Vansteenkiste may publish in the future.

Co-authorship network of co-authors of Johan Vansteenkiste

This figure shows the co-authorship network connecting the top 25 collaborators of Johan Vansteenkiste. A scholar is included among the top collaborators of Johan Vansteenkiste based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johan Vansteenkiste. Johan Vansteenkiste is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL 2015 ·Clinical Therapeutics ·Robert Pirker, Michael Hedenus, Johan Vansteenkiste, Enrique Hernández, (unknown), Jan-Henrik Terwey	5
2	Chemotherapy-induced anemia: the story of darbepoetin alfa 2013 ·Current Medical Research and Opinion ·Johan Vansteenkiste, (unknown), Steven Elliott, John A. Glaspy, Michael Hedenus	7
3	Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent 2012 ·Supportive Care in Cancer ·Robert Pirker, Melissa Pirolli, (unknown), (unknown), Jason C. Legg, Helen Collins, Johan Vansteenkiste	14
4	Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses 2012 ·Lung Cancer ·Johan Vansteenkiste, John A. Glaspy, David H. Henry, Heinz Ludwig, Robert Pirker, Dianne Tomita, Helen Collins, Jeffrey Crawford	35
5	Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia – systematic review and meta-analysis of randomised controlled trials 2012 ·Acta Oncologica ·Anat Gafter‐Gvili, Benaya Rozen‐Zvi, Liat Vidal, Leonard Leibovici, Johan Vansteenkiste, Uzi Gafter, Ofer Shpilberg	69
6	Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy 2012 ·Expert Review of Anticancer Therapy ·(unknown), Johan Vansteenkiste	6
7	Erythropoiesis-stimulating agents in cancer patients: reflections on safety 2011 ·Expert Review of Clinical Pharmacology ·(unknown), Johan Vansteenkiste	3
8	Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥10 g/dL: an exploratory analysis of a phase 3 trial 2011 ·Medical Oncology ·Jean-Luc Canon, Johan Vansteenkiste, Michael Hedenus, Pere Gascón, Carsten Bokemeyer, Heinz Ludwig, Jan B. Vermorken, Jason C. Legg, (unknown), (unknown)	12
9	Use of Erythropoiesis-stimulating Agents (ESAs) in Lung Cancer Patients: Study-level and Patient-level Meta-analyses of Safety Outcomes 2010 ·Journal of Thoracic Oncology ·(unknown), John A. Glaspy, Johan Vansteenkiste, Dahlia Henry, Dianne Tomita, Kenneth R. Bridges, H Ludwig	1
10	Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes 2010 ·British Journal of Cancer ·John A. Glaspy, Jeffrey Crawford, Johan Vansteenkiste, David H. Henry, Sudhakar Rao, Peter Bowers, Jesse A. Berlin, Dianne Tomita, Kenneth R. Bridges, Heinz Ludwig	176
11	Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial 2009 ·BMC Cancer ·Johan Vansteenkiste, Michael Hedenus, Pere Gascón, Carsten Bokemeyer, Heinz Ludwig, Jan B. Vermorken, Lisa Hamilton, (unknown), (unknown)	18
12	Darbepoetin alfa in the treatment of chemotherapy-induced anaemia 2008 ·Expert Opinion on Biological Therapy ·(unknown), Johan Vansteenkiste	9
13	Observational Aranesp® Survey to Investigate the Q3W Schedule (OASIS): a prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa 2008 ·Supportive Care in Cancer ·(unknown), (unknown), (unknown), F. Van Aelst, Koen Van Eygen, D. Galdermans, Didier Verhoeven, Marc Polus, (unknown), M. P. Derde, (unknown), Johan Vansteenkiste	6
14	Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals 2007 ·Expert Review of Anticancer Therapy ·Johan Vansteenkiste, (unknown)	3
15	Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia 2006 ·JNCI Journal of the National Cancer Institute ·Jean-Luc Canon, Johan Vansteenkiste, G. Bodoky, María‐Victoria Mateos, Laurent Bastit, Irene Ferreira, Greg Rossi, Rafael G. Amado	83
16	The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia 2005 ·Expert Opinion on Pharmacotherapy ·Johan Vansteenkiste, (unknown)	5
17	Gefitinib (Iressa®): a novel treatment for non-small cell lung cancer 2004 ·Expert Review of Anticancer Therapy ·Johan Vansteenkiste	43
18	Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline 2004 ·Supportive Care in Cancer ·Giuseppe Rossi, Robert Pirker, Johan Vansteenkiste, Dianne Tomita	27
19	Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia 2003 ·Expert Opinion on Biological Therapy ·Johan Vansteenkiste, Gregory Rossi, MaryAnn Foote	10
20	Evaluation of the Clinical Usefulness of Capnography Curves During a Hyperventilation Provocation Test in the Diagnosis of Hyperventilation Syndrome 1991 ·Acta Clinica Belgica ·Johan Vansteenkiste, F Rochette, (unknown)	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact